GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (STU:0KB1) » Definitions » Cyclically Adjusted Price-to-FCF

Humanigen (STU:0KB1) Cyclically Adjusted Price-to-FCF : (As of Sep. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Humanigen Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Humanigen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Humanigen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Cyclically Adjusted Price-to-FCF Chart

Humanigen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Humanigen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Humanigen's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Humanigen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humanigen's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Humanigen's Cyclically Adjusted Price-to-FCF falls into.



Humanigen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Humanigen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Humanigen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.055/127.3478*127.3478
=-0.055

Current CPI (Mar. 2023) = 127.3478.

Humanigen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 -3.164 98.518 -4.090
201309 -2.129 98.790 -2.744
201312 -1.792 98.326 -2.321
201403 -1.988 99.695 -2.539
201406 -1.720 100.560 -2.178
201409 -1.585 100.428 -2.010
201412 -1.375 99.070 -1.767
201503 -2.044 99.621 -2.613
201506 -1.265 100.684 -1.600
201509 -1.345 100.392 -1.706
201512 -1.778 99.792 -2.269
201603 -0.403 100.470 -0.511
201606 -1.359 101.688 -1.702
201609 -0.538 101.861 -0.673
201612 -0.191 101.863 -0.239
201703 -0.272 102.862 -0.337
201706 -0.234 103.349 -0.288
201709 -0.224 104.136 -0.274
201712 -0.109 104.011 -0.133
201803 -0.030 105.290 -0.036
201806 -0.015 106.317 -0.018
201809 -0.010 106.507 -0.012
201812 -0.010 105.998 -0.012
201903 -0.005 107.251 -0.006
201906 -0.013 108.070 -0.015
201909 -0.047 108.329 -0.055
201912 -0.022 108.420 -0.026
202003 -0.024 108.902 -0.028
202006 -0.647 108.767 -0.758
202009 -0.460 109.815 -0.533
202012 -0.377 109.897 -0.437
202103 -0.571 111.754 -0.651
202106 -0.959 114.631 -1.065
202109 -0.686 115.734 -0.755
202112 -0.452 117.630 -0.489
202203 -0.269 121.301 -0.282
202206 -0.340 125.017 -0.346
202209 -0.172 125.227 -0.175
202212 -0.115 125.222 -0.117
202303 -0.055 127.348 -0.055

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Humanigen  (STU:0KB1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Humanigen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Humanigen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Humanigen Business Description

Industry
Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Humanigen Headlines

No Headlines